source
- Pembrolizumab Plus BCG Elicits 92% CR Rate in BCG-Naive Very High-Risk T1 NMIBCPembrolizumab plus BCG achieved a 92% 6-month complete response rate in very high-risk T1 bladder cancer with no progression to muscle-invasive disease.onclive · 3mo ago↗ source
- STAT+: Takeda will pay $13.6 million to settle allegations it paid kickbacks to doctorsTakeda Pharmaceuticals agreed to pay $13.6 million to settle allegations that it paid kickbacks to doctors to prescribe an antidepressant.STAT · 3mo ago↗ source
- FDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder CancerThe FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.onclive · 3mo ago